论文部分内容阅读
早在1983年,有人报告用马抗人胸导管淋巴细胞球蛋白(ATDLG)治疗严重再生障碍性贫血。尽管没有把所有批号的ATDLG效果来进行比较,但ATDLG作为治疗严重再障还是有一定疗效的。本文作者选用两个批号的瑞士ATDLG来进行实验,从正常人外周血分离T细胞、粒细胞和单核细胞以及Burkitt’s Daudi细胞系(Ia类抗原阳性),并使用
As early as 1983, it was reported that the treatment of severe aplastic anemia with horse anti-thoracic ductal lymphocyte globulin (ATDLG). Although it is not possible to compare the ATDLG effects of all batches, ATDLG has some efficacy as a treatment for severe aplastic anemia. The authors selected two batches of Swiss ATDLG to perform experiments, isolating T cells, granulocytes and monocytes from normal human peripheral blood and Burkitt’s Daudi cell line (positive for type Ia antigen) and using